Pharmesis International (SGX:BFK) wholly owned subsidiary, Chengdu Kinna Pharma entered into a conditional sale and purchase agreement to acquire the remaining 19% equity interest in Sichuan Longlife Pharma from Chengdu Kinna Investment, a filing with the Singapore Exchange said on Monday.
The aggregate consideration payable by the group is 2.8 million yuan.
The acquisition is based on projections that Sichuan Longlife will secure a new procurement contract of herbal products from a new customer which could make the company profitable next year.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。